Penumbra Announces Initial Public Offering

September 17, 2015—Penumbra, Inc. announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $30.00 per share. The offering is scheduled to close on September 23, 2015, subject to customary closing conditions. Penumbra’s common stock is expected to begin trading (ticker symbol, “PEN”) on the New York Stock Exchange on September 18, 2015.  A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on September 17, 2015.

Penumbra, which is headquartered in Alameda, California, is a global interventional medical devices company with a portfolio of products for the treatment of ischemic stroke, hemorrhagic stroke, and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

On May 27, the company announced that the Ace64 aspiration thrombectomy system received 510(k) clearance from the United States Food and Drug Administration for the revascularization of large vessel occlusions in patients with acute ischemic stroke. The Ace64, which received CE Mark clearance in December 2014, is intended for acute ischemic stroke patients with large vessel occlusive disease within 8 hours of symptom onset.